T-Lymphocytes, Cytotoxic

• 

  Subject Areas on Research

  • 1982 resident's essay award: the immunologic effects of lymphoid irradiation in human and non-human primates: cellular changes and the potential for renal transplantation. 
  • A Phase I safety and immunogenicity trial of UBI microparticulate monovalent HIV-1 MN oral peptide immunogen with parenteral boost in HIV-1 seronegative human subjects. 
  • A canarypox vaccine expressing multiple human immunodeficiency virus type 1 genes given alone or with rgp120 elicits broad and durable CD8+ cytotoxic T lymphocyte responses in seronegative volunteers. 
  • A natural history of melanoma: serial gene expression analysis. 
  • A new nucleic acid-based agent inhibits cytotoxic T lymphocyte-mediated immune disorders. 
  • A novel method for detection and ex vivo expansion of HIV type 1-specific cytolytic T lymphocytes. 
  • A study of dendritic and endothelial cell interactions in colon cancer in a cell line and small mammal model. 
  • ADAM metallopeptidase domain 17 (ADAM17) is naturally processed through major histocompatibility complex (MHC) class I molecules and is a potential immunotherapeutic target in breast, ovarian and prostate cancers. 
  • Absence of immunodominant anti-Gag p17 (SL9) responses among Gag CTL-positive, HIV-uninfected vaccine recipients expressing the HLA-A*0201 allele. 
  • Active immunization using dendritic cells mixed with tumor cells inhibits the growth of primary breast cancer. 
  • Acute and chronic graft-versus-host disease in man. 
  • Acute graft-vs-host disease: pathobiology and management. 
  • Adeno-associated virus type 2 (AAV2) capsid-specific cytotoxic T lymphocytes eliminate only vector-transduced cells coexpressing the AAV2 capsid in vivo. 
  • Administration of a CD31-derived peptide delays the onset and significantly increases survival from lethal graft-versus-host disease. 
  • Adoptive transfer of cytotoxic T lymphocytes for the treatment of transplant-associated lymphoma. 
  • An EGFRvIII-targeted bispecific T-cell engager overcomes limitations of the standard of care for glioblastoma. 
  • An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants. 
  • Anti-tumour activity and store operated calcium entry: new roles in immunology. 
  • Antigen delivery by alpha(2)-macroglobulin enhances the cytotoxic T lymphocyte response. 
  • Antigen-capturing nanoparticles improve the abscopal effect and cancer immunotherapy. 
  • Antigen-presenting cells pulsed with unfractionated tumor-derived peptides are potent tumor vaccines. 
  • Association of chronic thromboxane inhibition with reduced in situ cytotoxic T cell activity in rejecting rat renal allografts. 
  • Augmentation of immune responses to HIV-1 and simian immunodeficiency virus DNA vaccines by IL-2/Ig plasmid administration in rhesus monkeys. 
  • Augmentation of syngeneic tumor-specific immunity by semiallogeneic cell hybrids. 
  • Autologous dendritic cells transfected with prostate-specific antigen RNA stimulate CTL responses against metastatic prostate tumors. 
  • Autologous lymph node cell-derived tumor-specific cytotoxic T-cells for use in adoptive immunotherapy of human melanoma. 
  • BET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression. 
  • Bone marrow-derived dendritic cells pulsed with tumor homogenate induce immunity against syngeneic intracerebral glioma. 
  • Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors. 
  • CD2-mediated IL-12-dependent signals render human gamma delta-T cells resistant to mitogen-induced apoptosis, permitting the large-scale ex vivo expansion of functionally distinct lymphocytes: implications for the development of adoptive immunotherapy strategies. 
  • CD200+ cytotoxic T lymphocytes in the tumor microenvironment are crucial for efficacious anti-PD-1/PD-L1 therapy. 
  • CD40 ligand is essential for generation of specific cytotoxic T cell responses in RNA-pulsed dendritic cell immunotherapy. 
  • CD8 CTL responses in vaccines: emerging patterns of HLA restriction and epitope recognition. 
  • CD8 positive T cells influence antigen-specific immune responses through the expression of chemokines. 
  • CD8+ T cell epitope-flanking mutations disrupt proteasomal processing of HIV-1 Nef. 
  • CD86 (B7-2) can function to drive MHC-restricted antigen-specific CTL responses in vivo. 
  • CEA loaded dendritic cell vaccines. 
  • CEA/CD3-bispecific T cell-engaging (BiTE) antibody-mediated T lymphocyte cytotoxicity maximized by inhibition of both PD1 and PD-L1. 
  • CTL cross reactivity between HIV strains. 
  • CX(3)CR1 drives cytotoxic CD4(+)CD28(-) T cells into the brain of multiple sclerosis patients. 
  • Calreticulin displays in vivo peptide-binding activity and can elicit CTL responses against bound peptides. 
  • Cancer immunotherapy with recombinant poliovirus induces IFN-dominant activation of dendritic cells and tumor antigen-specific CTLs. 
  • Carbohydrate recognition on MUC1-expressing targets enhances cytotoxicity of a T cell subpopulation. 
  • Caspase-7 activates ASM to repair gasdermin and perforin pores. 
  • Cells treated with TAP-2 antisense oligonucleotides are potent antigen-presenting cells in vitro and in vivo. 
  • Cellular and humoral immune responses to a canarypox vaccine containing human immunodeficiency virus type 1 Env, Gag, and Pro in combination with rgp120. 
  • Cellular immune response to cryptic epitopes during therapeutic gene transfer. 
  • Characterization of T cells expressing the gamma/delta antigen receptor in human renal allografts. 
  • Characterization of tumor-specific cytotoxic effector cells with a novel CD3-/Thy-1+ phenotype. 
  • Cholera toxin acts as a potent adjuvant for the induction of cytotoxic T-lymphocyte responses with non-replicating antigens. 
  • Clade B-based HIV-1 vaccines elicit cross-clade cytotoxic T lymphocyte reactivities in uninfected volunteers. 
  • Class I restricted CTL recognition of a soluble protein delivered by liposomes containing lipophilic polylysines. 
  • Combination gene therapy for liver metastasis of colon carcinoma in vivo. 
  • Combination treatment of murine tumors by adenovirus-mediated local B7/IL12 immunotherapy and radiotherapy. 
  • Comparative structural analysis of HLA-A2 antigens distinguishable by cytotoxic T lymphocytes. II. Variant DK1: evidence for a discrete CTL recognition region. 
  • Comparison of intradermal and intramuscular delivery followed by in vivo electroporation of SIV Env DNA in macaques. 
  • Comparison of systemic and mucosal delivery of 2 canarypox virus vaccines expressing either HIV-1 genes or the gene for rabies virus G protein. 
  • Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model. 
  • Containment of simian immunodeficiency virus infection in vaccinated macaques: correlation with the magnitude of virus-specific pre- and postchallenge CD4+ and CD8+ T cell responses. 
  • Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. 
  • Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. 
  • Conversion of effector CD4+ T cells to a CD8+ MHC II-recognizing lineage. 
  • Correlates of nontransmission in US women at high risk of human immunodeficiency virus type 1 infection through sexual exposure. 
  • Correlates of protective viruses damaging to HIV infection. 
  • Correlation between interferon- gamma secretion and cytotoxicity, in virus-specific memory T cells. 
  • Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques. 
  • Cross-clade human immunodeficiency virus (HIV)-specific cytotoxic T-lymphocyte responses in HIV-infected Zambians. 
  • Cryopreserved Mesenchymal Stromal Cells Are Susceptible to T-Cell Mediated Apoptosis Which Is Partly Rescued by IFNγ Licensing. 
  • Cutaneous γδ T-cell lymphomas: a spectrum of presentations with overlap with other cytotoxic lymphomas. 
  • Cysteine-tailed class I-binding peptides bind to CpG adjuvant and enhance primary CTL responses. 
  • Cytokine profiles in seronegative volunteers immunized with a recombinant canarypox and gp120 prime-boost HIV-1 vaccine. NIAID AIDS Vaccine Evaluation Group. 
  • Cytokine requirements for induction of systemic and mucosal CTL after nasal immunization. 
  • Cytotoxic T cell and neutralizing antibody responses to human immunodeficiency virus type 1 envelope with a combination vaccine regimen. AIDS Vaccine Evaluation Group. 
  • Cytotoxic-T-lymphocyte-mediated elimination of target cells transduced with engineered adeno-associated virus type 2 vector in vivo. 
  • DNA priming and recombinant pox virus boosters for an AIDS vaccine. 
  • Delivery of Synthetic mRNA Encoding FOXP3 Antigen into Dendritic Cells for Inflammatory Breast Cancer Immunotherapy. 
  • Dendritic Cell Immunotherapy for HIV-1 Infection Using Autologous HIV-1 RNA: A Randomized, Double-Blind, Placebo-Controlled Clinical Trial. 
  • Dendritic cell gene therapy. 
  • Dendritic cells cultured in anti-CD40 antibody-immobilized plates elicit a highly efficient peptide-specific T-cell response. 
  • Dendritic cells improve the generation of Epstein-Barr virus-specific cytotoxic T lymphocytes for the treatment of posttransplantation lymphoma. 
  • Dendritic cells infected with a vaccinia vector carrying the human gp100 gene simultaneously present multiple specificities and elicit high-affinity T cells reactive to multiple epitopes and restricted by HLA-A2 and -A3. 
  • Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. 
  • Depletion of dendritic cells delays ovarian cancer progression by boosting antitumor immunity. 
  • Developing an HIV vaccine. 
  • Direct interaction between HLA-B and carbamazepine activates T cells in patients with Stevens-Johnson syndrome. 
  • Direct ultrastructural evidence of target-directed polarization by cytotoxic lymphocytes in lesions of human graft-vs-host disease. 
  • Dual-Affinity Re-Targeting proteins direct T cell-mediated cytolysis of latently HIV-infected cells. 
  • Dynamic immune responses maintain cytotoxic T lymphocyte epitope mutations in transmitted simian immunodeficiency virus variants. 
  • EL-4 metastases in spleen and bone marrow suppress the NK activity generated in these organs. 
  • Effective induction of simian immunodeficiency virus-specific systemic and mucosal immune responses in primates by vaccination with proviral DNA producing intact but noninfectious virions. 
  • Effectiveness of combined interleukin 2 and B7.1 vaccination strategy is dependent on the sequence and order: a liposome-mediated gene therapy treatment for bladder cancer. 
  • Effector mechanisms in transplant rejection. 
  • Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. 
  • Engineering DNA vaccines via co-delivery of co-stimulatory molecule genes. 
  • Enhanced activation of human dendritic cells by inducible CD40 and Toll-like receptor-4 ligation. 
  • Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins. 
  • Enhanced type 1 immunity after secondary viral challenge in mice primed as neonates. 
  • Enhancement of anti-tumor immunity through local modulation of CTLA-4 and GITR by dendritic cells. 
  • Epstein - Barr virus specific cytotoxic T lymphocytes for the treatment of severe epstein-barr virus mucocutaneous ulcer. 
  • Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. 
  • Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. 
  • Evidence that pretransplant donor blood transfusion prevents rat renal allograft dysfunction but not the in situ cellular alloimmune or morphologic manifestations of rejection. 
  • Evolutionarily conserved epitopes on human immunodeficiency virus type 1 (HIV-1) and feline immunodeficiency virus reverse transcriptases detected by HIV-1-infected subjects. 
  • Ex vivo expanded human CD4+ regulatory NKT cells suppress expansion of tumor antigen-specific CTLs. 
  • Excellent safety and tolerability of the human immunodeficiency virus type 1 pGA2/JS2 plasmid DNA priming vector vaccine in HIV type 1 uninfected adults. 
  • FN18-CRM9 immunotoxin promotes tolerance in primate renal allografts. 
  • Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. 
  • Functionally inert HIV-specific cytotoxic T lymphocytes do not play a major role in chronically infected adults and children. 
  • Gene transfer to the thymus. A means of abrogating the immune response to recombinant adenovirus. 
  • Generation of autologous tumor-specific cytotoxic T-cells using HLA-A region matched allogeneic melanoma. 
  • Generation of human autologous melanoma-specific cytotoxic T-cells using HLA-A2-matched allogeneic melanomas. 
  • Generation of melanoma-specific, cytotoxic CD4(+) T helper 2 cells: requirement of both HLA-DR15 and Fas antigens on melanomas for their lysis by Th2 cells. 
  • Generation of primary tumor-specific cytotoxic T lymphocytes from autologous and human lymphocyte antigen class I-matched allogeneic peripheral blood lymphocytes by B7 gene-modified melanoma cells. 
  • Graft hyporeactivity induced by donor-derived dendritic cell progenitors. 
  • Graft hyporeactivity induced by immature donor-derived dendritic cells. 
  • Graft-versus-host disease prevention by rapamycin: cellular mechanisms. 
  • Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. 
  • HDAC6 regulates the dynamics of lytic granules in cytotoxic T lymphocytes. 
  • HER2/neu-derived peptides are shared antigens among human non-small cell lung cancer and ovarian cancer. 
  • HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. 
  • HIV immunization. Fresh pathways to follow. 
  • HIV type 1 vaccine-induced cytotoxic T cell responses in phase I clinical trials: detection, characterization, and quantitation. 
  • HIV vaccine development at Duke University Medical Center. 
  • HIV vaccine development: perspective. 
  • HIV vaccines. Viral envelope fails to deliver? 
  • HIV-1 GP120-mediated immune suppression and lymphocyte destruction in the absence of viral infection. 
  • HLA class I serotypes and cytotoxic T-lymphocyte responses among human immunodeficiency virus-1-uninfected Thai volunteers immunized with ALVAC-HIV in combination with monomeric gp120 or oligomeric gp160 protein boosting. 
  • HLA-A and -B allele expression and ability to develop anti-Gag cross-clade responses in subtype C HIV-1-infected Ethiopians. 
  • Herpesvirus saimiri transformation of HIV type 1 suppressive CD8+ lymphocytes from an HIV type 1-infected asymptomatic individual. 
  • High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. 
  • High-throughput identification and dendritic cell-based functional validation of MHC class I-restricted Mycobacterium tuberculosis epitopes. 
  • Highly attenuated vaccine strains of simian immunodeficiency virus protect against vaginal challenge: inverse relationship of degree of protection with level of attenuation. 
  • Human T cells specifically activated against autologous malignant melanoma. 
  • Human cytotoxic T cells specific for autologous melanoma cells: successful generation from lymph node cells in seven consecutive cases. 
  • Human dendritic cells transfected with RNA encoding prostate-specific antigen stimulate prostate-specific CTL responses in vitro. 
  • Human immunodeficiency virus type 1-specific cytotoxic T lymphocyte activity is inversely correlated with HIV type 1 viral load in HIV type 1-infected long-term survivors. 
  • Human xenograft-nude mouse model of adoptive immunotherapy with human melanoma-specific cytotoxic T-cells. 
  • IFN-gamma production in response to neuropathogenic Cas-Br-M murine leukemia virus infection. 
  • IL-12 DNA as molecular vaccine adjuvant increases the cytotoxic T cell responses and breadth of humoral immune responses in SIV DNA vaccinated macaques. 
  • IL-6 trans-signaling licenses mouse and human tumor microvascular gateways for trafficking of cytotoxic T cells. 
  • IL-7 enhancement of antigen-driven activation/expansion of HIV-1-specific cytotoxic T lymphocyte precursors (CTLp). 
  • Identification of highly conserved and broadly cross-reactive HIV type 1 cytotoxic T lymphocyte epitopes as candidate immunogens for inclusion in Mycobacterium bovis BCG-vectored HIV vaccines. 
  • Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer. 
  • IgA transcytosis and antigen recognition govern ovarian cancer immunity. 
  • Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. 
  • Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. 
  • Immune responses in asymptomatic HIV-1-infected patients after HIV-DNA immunization followed by highly active antiretroviral treatment. 
  • Immune selection after antigen-specific immunotherapy of melanoma. 
  • Immunity to MHC class I antigen after direct DNA transfer into skeletal muscle. 
  • Immunization with mutant p53- and K-ras-derived peptides in cancer patients: immune response and clinical outcome. 
  • Immunogenic determinants of a neuropathogenic murine leukemia virus. 
  • Immunologic and virologic analyses of an acutely HIV type 1-infected patient with extremely rapid disease progression. 
  • Immunologic characterization of CD7-deficient mice. 
  • Immunologic suppression mediated by genetically modified hepatocytes expressing secreted allo-MHC class I molecules. 
  • Immunologic targeting of FOXP3 in inflammatory breast cancer cells. 
  • Immunopathogenic events in acute infection of rhesus monkeys with simian immunodeficiency virus of macaques. 
  • Immunoproteasome down-modulation enhances the ability of dendritic cells to stimulate antitumor immunity. 
  • Immunotherapeutic potential of tumor antigen-pulsed and unpulsed dendritic cells generated from murine bone marrow. 
  • Immunotherapy for malignant melanoma with a tumor cell vaccine. 
  • Immunotherapy of cancer using dendritic cells. 
  • Immunotherapy with vaccines combining MHC class II/CD80+ tumor cells with interleukin-12 reduces established metastatic disease and stimulates immune effectors and monokine induced by interferon gamma. 
  • Impact of immune escape mutations on HIV-1 fitness in the context of the cognate transmitted/founder genome. 
  • Implications of leukoregulin to autologous tumor-specific human T-cell populations. 
  • In situ and systemic cellular immunity associated with orthotopic rat liver allograft acceptance or rejection. 
  • In vitro induction of primary, antigen-specific CTL from human peripheral blood mononuclear cells stimulated with synthetic peptides. 
  • In vitro priming and expansion of cytomegalovirus-specific Th1 and Tc1 T cells from naive cord blood lymphocytes. 
  • In vivo cytotoxic T lymphocyte induction with soluble proteins administered in liposomes. 
  • Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. 
  • Induction in vitro of primary cytotoxic T-lymphocyte responses with DNA encoding herpes simplex virus proteins. 
  • Induction of CD4(+) and CD8(+) T-cell responses to the human stromal antigen, fibroblast activation protein: implication for cancer immunotherapy. 
  • Induction of Wilms' tumor protein (WT1)-specific antitumor immunity using a truncated WT1-expressing adenovirus vaccine. 
  • Induction of carcinoembryonic antigen (CEA)-specific cytotoxic T-lymphocyte responses in vitro using autologous dendritic cells loaded with CEA peptide or CEA RNA in patients with metastatic malignancies expressing CEA. 
  • Induction of cytotoxic T cell responses and tumor immunity against unrelated tumors using telomerase reverse transcriptase RNA transfected dendritic cells. 
  • Induction of cytotoxic T cell responses in newborn mice by DNA immunization. 
  • Induction of cytotoxic T lymphocytes with dendritic cells transfected with human papillomavirus E6 and E7 RNA: implications for cervical cancer immunotherapy. 
  • Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. 
  • Induction of immune responses and clinical efficacy in a phase II trial of IDM-2101, a 10-epitope cytotoxic T-lymphocyte vaccine, in metastatic non-small-cell lung cancer. 
  • Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. 
  • Induction of neutralizing antibodies and cytotoxic T lymphocytes in Balb/c mice immunized with virus-like particles presenting a gp120 molecule from a HIV-1 isolate of clade A. 
  • Induction of polyclonal prostate cancer-specific CTL using dendritic cells transfected with amplified tumor RNA. 
  • Induction of primary carcinoembryonic antigen (CEA)-specific cytotoxic T lymphocytes in vitro using human dendritic cells transfected with RNA. 
  • Induction of primary, antiviral cytotoxic, and proliferative responses with antigens administered via dendritic cells. 
  • Induction of primary, human antigen-specific cytotoxic T lymphocytes in vitro using dendritic cells pulsed with peptides. 
  • Induction of protective CTL responses in newborn mice by a murine retrovirus. 
  • Induction of specific tolerance by intrathymic injection of recipient muscle cells transfected with donor class I major histocompatibility complex. 
  • Induction of tumor immunity and cytotoxic T lymphocyte responses using dendritic cells transfected with messenger RNA amplified from tumor cells. 
  • Induction of tumor-specific cytotoxic T lymphocytes in cancer patients by autologous tumor RNA-transfected dendritic cells. 
  • Influence of CD4 T cells and the source of major histocompatibility complex class II-restricted peptides on cytotoxic T-cell priming by dendritic cells. 
  • Influence of HLA-C expression level on HIV control. 
  • Inhibition of PCSK9 potentiates immune checkpoint therapy for cancer. 
  • Inhibition of T cell costimulation by VCAM-1 prevents murine graft-versus-host disease across minor histocompatibility barriers. 
  • Inhibition of invariant chain expression in dendritic cells presenting endogenous antigens stimulates CD4+ T-cell responses and tumor immunity. 
  • Inhibition of lymphocyte proliferation by a synthetic peptide homologous to envelope proteins of human and animal retroviruses. 
  • Inhibition of murine cytotoxic T lymphocyte activity by a synthetic retroviral peptide and abrogation of this activity by IL. 
  • Inhibition of the growth of human melanoma xenografts in nude mice by human tumor-specific cytotoxic T-cells. 
  • Initiation of antiretroviral therapy during primary HIV-1 infection induces rapid stabilization of the T-cell receptor beta chain repertoire and reduces the level of T-cell oligoclonality. 
  • Interferon-gamma reduces melanosomal antigen expression and recognition of melanoma cells by cytotoxic T cells. 
  • Interleukin 2 produced by activated B lymphocytes acts as an autocrine proliferation-inducing lymphokine. 
  • Intranasal immunization with CTL epitope peptides from HIV-1 or ovalbumin and the mucosal adjuvant cholera toxin induces peptide-specific CTLs and protection against tumor development in vivo. 
  • Intranasal immunization with cytotoxic T-lymphocyte epitope peptide and mucosal adjuvant cholera toxin: selective augmentation of peptide-presenting dendritic cells in nasal mucosa-associated lymphoid tissue. 
  • JAK-STAT activation contributes to cytotoxic T cell-mediated basal cell death in human chronic lung allograft dysfunction. 
  • Lack of evidence for MHC-unrestricted (atypical) recognition of mucin by mucinous pancreatic tumour-reactive T-cells. 
  • Lack of viral escape and defective in vivo activation of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes in rapidly progressive infection. 
  • Lessons from a multisite international trial in the Caribbean and South America of an HIV-1 Canarypox vaccine (ALVAC-HIV vCP1452) with or without boosting with MN rgp120. 
  • Leukotriene C4 induces migration of human monocyte-derived dendritic cells without loss of immunostimulatory function. 
  • Liposomal delivery of soluble protein antigens for class I MHC-mediated antigen presentation. 
  • Loss of tumorigenicity following in vitro MuLV infection is associated with induction of peritoneal natural killer cell activity. 
  • Lymphocyte subsets in Chediak-Higashi patients. 
  • M-HIFU inhibits tumor growth, suppresses STAT3 activity and enhances tumor specific immunity in a transplant tumor model of prostate cancer. 
  • MAGE-1-specific precursor cytotoxic T-lymphocytes present among tumor-infiltrating lymphocytes from a patient with breast cancer: characterization and antigen-specific activation. 
  • MHC class I-presented lung cancer-associated tumor antigens identified by immunoproteomics analysis are targets for cancer-specific T cell response. 
  • MHC class I-presented tumor antigens identified in ovarian cancer by immunoproteomic analysis are targets for T-cell responses against breast and ovarian cancer. 
  • MHC-restricted recognition of autologous melanoma by tumor-specific cytotoxic T cells. Evidence for restriction by a dominant HLA-A allele. 
  • Macrophage colony-stimulating factor can modulate immune responses and attract dendritic cells in vivo. 
  • Major histocompatibility complex class I alleles associated with slow simian immunodeficiency virus disease progression bind epitopes recognized by dominant acute-phase cytotoxic-T-lymphocyte responses. 
  • Maximal exercise increases mucosal associated invariant T cell frequency and number in healthy young men. 
  • Melanoma-specific cytotoxic T cells generated from peripheral blood lymphocytes. Implications of a renewable source of precursors for adoptive cellular immunotherapy. 
  • Metabolic reprogramming towards aerobic glycolysis correlates with greater proliferative ability and resistance to metabolic inhibition in CD8 versus CD4 T cells. 
  • Metastatic colorectal cancer cells from patients previously treated with chemotherapy are sensitive to T-cell killing mediated by CEA/CD3-bispecific T-cell-engaging BiTE antibody. 
  • Modulation of alloimmunity to major histocompatibility complex class I by cotransfer of cytokine genes in vivo. 
  • Modulation of amplitude and direction of in vivo immune responses by co-administration of cytokine gene expression cassettes with DNA immunogens. 
  • Modulation of in vitro autologous melanoma-specific cytotoxic T-cell responses by phorbol dibutyrate and ionomycin. 
  • Molecular and immunological analysis of genetic prostate specific antigen (PSA) vaccine. 
  • Monoclonal antibodies to T-helper/inducer and T-suppressor/cytotoxic lymphocyte subsets recognize antigens on splenic sinusoidal lining cells. 
  • Monocytes as a Cellular Vaccine Platform to Induce Antitumor Immunity. 
  • Multiple CTL specificities against autologous HIV-1-infected BLCLs. 
  • Multispecific vaccine-induced mucosal cytotoxic T lymphocytes reduce acute-phase viral replication but fail in long-term control of simian immunodeficiency virus SIVmac239. 
  • Murine dendritic cells transfected with human GP100 elicit both antigen-specific CD8(+) and CD4(+) T-cell responses and are more effective than DNA vaccines at generating anti-tumor immunity. 
  • NKG2D-mediated activation of cytotoxic lymphocytes: unique signaling pathways and distinct functional outcomes. 
  • Nasal immunization with a recombinant HIV gp120 and nanoemulsion adjuvant produces Th1 polarized responses and neutralizing antibodies to primary HIV type 1 isolates. 
  • Neutralizing antibodies associated with viremia control in a subset of individuals after treatment of acute human immunodeficiency virus type 1 infection. 
  • Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations. 
  • Oligoclonal CD8 lymphocytes from persons with asymptomatic human immunodeficiency virus (HIV) type 1 infection inhibit HIV-1 replication. 
  • Origin and Role of a Subset of Tumor-Associated Neutrophils with Antigen-Presenting Cell Features in Early-Stage Human Lung Cancer. 
  • Overlapping epitopes in human immunodeficiency virus type 1 gp120 presented by HLA A, B, and C molecules: effects of viral variation on cytotoxic T-lymphocyte recognition. 
  • Overview of melanoma vaccines and promising approaches. 
  • Passive immunotherapy in simian immunodeficiency virus-infected macaques accelerates the development of neutralizing antibodies. 
  • Peptide-conjugated PAMAM dendrimer as a universal DNA vaccine platform to target antigen-presenting cells. 
  • Phase 1 study in patients with metastatic melanoma of immunization with dendritic cells presenting epitopes derived from the melanoma-associated antigens MART-1 and gp100. 
  • Phase 2 study of an HIV-1 canarypox vaccine (vCP1452) alone and in combination with rgp120: negative results fail to trigger a phase 3 correlates trial. 
  • Phenotype and function of T cells propagated from donor-specific blood transfusion enhanced and autologous blood transfused rejecting rat renal allografts. 
  • Phenotypic and functional characterization of cytotoxic T lymphocytes by flow cytometry. 
  • Phenotypic and functional consequences of herpesvirus saimiri infection of human CD8+ cytotoxic T lymphocytes. 
  • Piceatannol in combination with low doses of cyclosporine A prolongs kidney allograft survival in a stringent rat transplantation model. 
  • Polymorphisms in HLA class I genes associated with both favorable prognosis of human immunodeficiency virus (HIV) type 1 infection and positive cytotoxic T-lymphocyte responses to ALVAC-HIV recombinant canarypox vaccines. 
  • Preparation of apoptotic tumor cells with replication-incompetent HSV augments the efficacy of dendritic cell vaccines. 
  • Prevention of graft-versus-host disease while preserving graft-versus-leukemia effect after selective depletion of host-reactive T cells by photodynamic cell purging process. 
  • Primary cutaneous aggressive epidermotropic cytotoxic T-cell lymphomas: reappraisal of a provisional entity in the 2016 WHO classification of cutaneous lymphomas. 
  • Priming for virus-specific CD8+ but not CD4+ cytotoxic T lymphocytes with synthetic lipopeptide is influenced by acylation units and liposome encapsulation. 
  • Priming of anti-human immunodeficiency virus (HIV) CD8+ cytotoxic T cells in vivo by carrier-free HIV synthetic peptides. 
  • Prolonged survival of class II transactivator-deficient cardiac allografts. 
  • Prospects for cellular immunotherapy for metastatic melanoma. 
  • Protection of rhesus monkeys against infection with minimally pathogenic simian-human immunodeficiency virus: correlations with neutralizing antibodies and cytotoxic T cells. 
  • Protein kinase B controls transcriptional programs that direct cytotoxic T cell fate but is dispensable for T cell metabolism. 
  • QS-21 promotes an adjuvant effect allowing for reduced antigen dose during HIV-1 envelope subunit immunization in humans. 
  • Rapid and slow progressors differ by a single MHC class I haplotype in a family of MHC-defined rhesus macaques infected with SIV. 
  • Rare HIV-1 transmitted/founder lineages identified by deep viral sequencing contribute to rapid shifts in dominant quasispecies during acute and early infection. 
  • Receptor mediated and fluid phase pathways for internalization of the ER Hsp90 chaperone GRP94 in murine macrophages. 
  • Recognition and killing of autologous, primary glioblastoma tumor cells by human cytomegalovirus pp65-specific cytotoxic T cells. 
  • Recognition and lysis of human melanoma by a CD3+, CD4+, CD8- T-cell clone restricted by HLA-A2. 
  • Recognition by and in vitro induction of cytotoxic T lymphocytes against predicted epitopes of the immediate-early protein ICP27 of herpes simplex virus. 
  • Recognition of HLA-A2 mutant and variant target cells by an HLA-A2 allospecific human cytotoxic T lymphocyte line. 
  • Recombinant poxvirus boosting of DNA-primed rhesus monkeys augments peak but not memory T lymphocyte responses. 
  • Recombinant rubella vectors elicit SIV Gag-specific T cell responses with cytotoxic potential in rhesus macaques. 
  • Redirecting cytotoxic T lymphocyte responses with T-cell receptor transgenes. 
  • Redirection of Cord Blood T Cells and Natural Killer Cells for Elimination of Autologous HIV-1-Infected Target Cells Using Bispecific DART® Molecules. 
  • Reduced thymic maturation but normal effector function of CD8+ T cells in CD8 beta gene-targeted mice. 
  • Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination. 
  • Regression of human kidney cancer following allogeneic stem cell transplantation is associated with recognition of an HERV-E antigen by T cells. 
  • Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. 
  • Regulation of T cell function by microRNA-720. 
  • Renal allograft-infiltrating lymphocytes. A prospective analysis of in vitro growth characteristics and clinical relevance. 
  • Replication-defective canarypox (ALVAC) vectors effectively activate anti-human immunodeficiency virus-1 cytotoxic T lymphocytes present in infected patients: implications for antigen-specific immunotherapy. 
  • Requirement of cognate CD4+ T-cell recognition for the regulation of allospecific CTL by human CD4+ CD127- CD25+ FOXP3+ cells generated in MLR. 
  • Rescuing imperfect antigens for immuno-oncology. 
  • Resistance to human immunodeficiency virus type 1 in vitro as a surrogate of vaccine-induced protective immunity. 
  • Reversion mutations in patients with leukocyte adhesion deficiency type-1 (LAD-1). 
  • Role of LAT in the granule-mediated cytotoxicity of CD8 T cells. 
  • Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses. 
  • Safety and immunogenicity of Env 2-3, a human immunodeficiency virus type 1 candidate vaccine, in combination with a novel adjuvant, MTP-PE/MF59. NIAID AIDS Vaccine Evaluation Group. 
  • Safety and immunogenicity of a CTL multiepitope peptide vaccine for HIV with or without GM-CSF in a phase I trial. 
  • Safety and immunogenicity of a canarypox-vectored human immunodeficiency virus Type 1 vaccine with or without gp120: a phase 2 study in higher- and lower-risk volunteers. 
  • Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. 
  • Safety and immunogenicity of a live recombinant canarypox virus expressing HIV type 1 gp120 MN MN tm/gag/protease LAI (ALVAC-HIV, vCP205) followed by a p24E-V3 MN synthetic peptide (CLTB-36) administered in healthy volunteers at low risk for HIV infection. AGIS Group and L'Agence Nationale de Recherches sur Le Sida. 
  • Safety and immunogenicity of an HIV-1 recombinant canarypox vaccine in newborns and infants of HIV-1-infected women. 
  • Safety and immunogenicity of an HLA-based HIV envelope polyvalent synthetic peptide immunogen. DATRI 010 Study Group. Division of AIDS Treatment Research Initiative. 
  • Safety and immunogenicity of cytotoxic T-lymphocyte poly-epitope, DNA plasmid (EP HIV-1090) vaccine in healthy, human immunodeficiency virus type 1 (HIV-1)-uninfected adults. 
  • Selective inhibition of natural killer activity by the monoclonal antibodies OKT10 and VEP10 at the single cell level. 
  • Simian immunodeficiency virus DNA vaccine trial in macaques. 
  • Simian-human immunodeficiency virus SHIV89.6-induced protection against intravaginal challenge with pathogenic SIVmac239 is independent of the route of immunization and is associated with a combination of cytotoxic T-lymphocyte and alpha interferon responses. 
  • Similarities in long-term alloreactive T cell lines propagated from transfusion-enhanced and control-rejecting rat renal allografts. 
  • Soluble proteins delivered to dendritic cells via pH-sensitive liposomes induce primary cytotoxic T lymphocyte responses in vitro. 
  • Specific activation strategies for amplification of low CTL signals. 
  • Split tolerance induced by immunotoxin in a rhesus kidney allograft model. 
  • Split tolerance permits safe Ad5-GUCY2C-PADRE vaccine-induced T-cell responses in colon cancer patients. 
  • Structural analysis of an HLA-B7 antigen variant detected by cytotoxic T lymphocytes. 
  • Structural analysis of the functional sites of class I HLA antigens. 
  • Studies of tumor-infiltrating lymphocytes from a human choroidal melanoma. 
  • Studies on the mechanism and specificity of the effect of the synthetic random copolymer GLAT on graft-versus-host disease. 
  • Suppression of pullulanase-induced cytotoxic T cell response with a dual promoter in GSD IIIa mice. 
  • Synergy between tumor immunotherapy and antiangiogenic therapy. 
  • Synthetic peptide in mineral oil adjuvant elicits simian immunodeficiency virus-specific CD8+ cytotoxic T lymphocytes in rhesus monkeys. 
  • T cell large granular lymphocyte leukemia associated with rheumatoid arthritis and neutropenia. 
  • TCR repertoire characteristics predict clinical response to adoptive CTL therapy against nasopharyngeal carcinoma. 
  • Targeting Endoglin-Expressing Regulatory T Cells in the Tumor Microenvironment Enhances the Effect of PD1 Checkpoint Inhibitor Immunotherapy. 
  • Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. 
  • Targeting the Leukemia Antigen PR1 with Immunotherapy for the Treatment of Multiple Myeloma. 
  • The Bowman's shield: a tribute to translational science and Detlef Schlöndorff. 
  • The antiapoptotic protein Bcl-xL is dispensable for the development of effector and memory T lymphocytes. 
  • The clinical application of monoclonal antibody therapies in renal transplantation. 
  • The effector component of the cytotoxic T-lymphocyte response has a biphasic pattern after burn injury. 
  • The impact of HIV-1 infection on phenotypic and functional parameters of cellular immunity in chimpanzees. 
  • The influence of RS-61443 on antibody-mediated rejection. 
  • The isoforms of phospholipase C-gamma are differentially used by distinct human NK activating receptors. 
  • The requirements for CTL-mediated rejection of cancer in humans: NKG2D and its role in the immune responsiveness of melanoma. 
  • The role for interleukin-12 therapy of cutaneous T cell lymphoma. 
  • The role of ACAID and CD4+CD25+FOXP3+ regulatory T cells on CTL function against MHC alloantigens. 
  • The role of HLA class I antigens in recognition of melanoma cells by tumor-specific cytotoxic T lymphocytes. Evidence for shared tumor antigens. 
  • The role of IL-13 in the generation of dendritic cells in vitro. 
  • Threshold levels of gene expression of the melanoma antigen gp100 correlate with tumor cell recognition by cytotoxic T lymphocytes. 
  • Toll-like receptor 3 adjuvant in combination with virus-like particles elicit a humoral response against HIV. 
  • Transduction of human melanoma cells with the gamma interferon gene enhances cellular immunity. 
  • Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. 
  • Transfer of HIV-1-specific cytotoxic T lymphocytes to an AIDS patient leads to selection for mutant HIV variants and subsequent disease progression. 
  • Transforming growth factor β-mediated suppression of antitumor T cells requires FoxP1 transcription factor expression. 
  • Treatment of human melanoma hepatic metastases in nude mice with human cytotoxic T lymphocytes. 
  • Two forms of the T-cell receptor gamma protein found on peripheral blood cytotoxic T lymphocytes. 
  • Ultraviolet-light-inactivated Cas-Br-M murine leukemia virus induces a protective CD8+ cytotoxic T lymphocyte response in newborn mice. 
  • Understanding the response to immunotherapy in humans. 
  • Use of synthetic peptides in primates to induce high-titered neutralizing antibodies and MHC class I-restricted cytotoxic T cells against acquired immunodeficiency syndrome retroviruses: an HLA-based vaccine strategy. 
  • Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. 
  • Vaccination with mRNAs encoding tumor-associated antigens and granulocyte-macrophage colony-stimulating factor efficiently primes CTL responses, but is insufficient to overcome tolerance to a model tumor/self antigen. 
  • Vaccine-elicited V3 loop-specific antibodies in rhesus monkeys and control of a simian-human immunodeficiency virus expressing a primary patient human immunodeficiency virus type 1 isolate envelope. 
  • Vaccine-elicited immune responses prevent clinical AIDS in SHIV(89.6P)-infected rhesus monkeys. 
  • Variables affecting the T cell receptor V beta repertoire heterogeneity of T cells infiltrating human renal allografts. 
  • gammadelta T cells: a new frontier for immunotherapy? 
• 

  Keywords of People

  • Ferrari, Guido, Professor in Surgery, Molecular Genetics and Microbiology
  • McLendon, Roger Edwin, Professor of Pathology, Pathology
  • Sampson, John Howard, Robert H., M.D. and Gloria Wilkins Professor of Neurosurgery, in the School of Medicine, Biomedical Engineering
  • Shinohara, Mari L., Professor of Integrative Immunobiology, Cell Biology
  • Weinhold, Kent James, Joseph W. and Dorothy W. Beard Distinguished Professor of Experimental Surgery, Integrative Immunobiology